| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9855f853f24337072ce02f44383942c9 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70532 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H10-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H20-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B40-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N27-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B40-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B25-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H20-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16B40-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N21-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G06F18-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6851
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5743
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H50-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G16H40-63 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16H50-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16H40-63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16H20-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B40-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G16B40-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate |
2016-07-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0066944fab2e4cc56ce9138ae1b722e7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d5080ba90e79bdf07cdf32457639384d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cd9abd3e4255d01c15e537283b9748f8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d3b8078a963863b6455d6417e17641e2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_80105fca56ad76f0ac13a8a45d6ebe4d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cddcbc8202e2f5b8f6efbf9f7dde859b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cdc4e928e16d85086ee7bbc3736fc67f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_55ec57ea1f041aa79da4301ecc94d8f6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f92f1e2e5785a07a33096806b6a37adb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_345eaed90b2bf0a681fcdae4db15f4e9 |
| publicationDate |
2021-02-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3779998-A1 |
| titleOfInvention |
Predictive test for melanoma patient benefit from pd-1 antibody drug and classifier development methods |
| abstract |
A method is disclosed of predicting cancer patient response to immune checkpoint inhibitors, e.g., an antibody drug blocking ligand activation of programmed cell death 1 (PD-1) or CTLA4. The method includes obtaining mass spectrometry data from a blood-based sample of the patient, obtaining integrated intensity values in the mass spectrometry data of a multitude of pre-determined mass-spectral features; and operating on the mass spectral data with a programmed computer implementing a classifier. The classifier compares the integrated intensity values with feature values of a training set of class-labeled mass spectral data obtained from a multitude of melanoma patients with a classification algorithm and generates a class label for the sample. A class label "early" or the equivalent predicts the patient is likely to obtain relatively less benefit from the antibody drug and the class label "late" or the equivalent indicates the patient is likely to obtain relatively greater benefit from the antibody drug. |
| priorityDate |
2015-07-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |